Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversible P2Y12 platelet inhibitor.
## Primary Indications
* **Acute Coronary Syndromes (ACS):** To reduce the rate of thrombotic cardiovascular events (including stent thrombosis) in patients with a history of myocardial infarction (MI).
* **Atrial Fibrillation:** To reduce the rate of thrombotic cardiovascular events in patients with atrial fibrillation and at least one risk factor for stroke.
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily for at least 12 months, or up to 30 months, in combination with aspirin.
* **In patients with a history of MI older than 1 year and treated with aspirin:** For patients with additional thrombotic risk, 60 mg orally twice daily may be considered.
* **Atrial Fibrillation:**
* **Maintenance Dose:** 90 mg orally twice daily, in combination with aspirin or other antiplatelet therapy.
## Pediatric Dosing
* Ticagrelor is not recommended for use in pediatric patients. Safety and efficacy have not been established.
## Dose Adjustments
* **Hepatic Impairment:** No dose adjustment is recommended in patients with mild to moderate hepatic impairment. Use with caution in severe hepatic impairment due to potential for increased exposure.
* **Renal Impairment:** No dose adjustment is recommended in patients with mild to moderate renal impairment. Use with caution in severe renal impairment.
## Contraindications
* Active pathological bleeding.
* History of transient ischemic attack (TIA) or stroke while on ticagrelor.
* Known hypersensitivity to ticagrelor or any of its excipients.
## Adverse Effects
* **Major Bleeding:** This is the most significant risk. Bleeding can occur at any site.
* **Dyspnea:** Transient shortness of breath, often resolves with continued therapy.
* **Bradycardia:** Symptomatic bradycardia can occur.
* **Ventricular pauses:** Asymptomatic ventricular pauses may be observed.
* **Hyperuricemia:** Increased uric acid levels.
* **Angioedema:** Although rare, can be severe.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase ticagrelor exposure. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) can decrease ticagrelor exposure.
* **Aspirin:** Increased risk of bleeding when used in combination. Duration of combination therapy should be individualized.
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding.
* **Statins:** Potential for increased simvastatin/atorvastatin concentrations. Avoid simvastatin doses >40 mg and atorvastatin doses >80 mg.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Monitor for dyspnea and bradycardia.
* Electrolyte levels may be monitored due to potential for hyperkalemia.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, unlike clopidogrel.
* It is administered twice daily.
* A loading dose is required for ACS initiation.
* Discontinuation of ticagrelor should be avoided if possible, as it increases the risk of thrombotic events. If discontinuation is necessary for planned surgery, consider the risks and benefits.
* Maintenance of ticagrelor therapy for at least 12 months in ACS patients is generally recommended.
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information for complete details and to ensure patient safety.
